Introgen Therapeutics Inc.

News - Introgen Therapeutics Inc.

Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File

2008-09-02 09:00:43

Introgen Therapeutics, Inc.

Introgen's ADVEXIN(R) MAA Accepted for Review By European Medicines Agency

2008-08-18 09:01:01

Introgen Therapeutics, Inc.

Introgen Appoints James E. Rothman, Ph.D., To Board of Directors

2008-08-12 09:01:36

Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced the appointment of James E. Rothman, Ph.D., to the Company's board of directors. In September 2008, Dr.

ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit As Compared to Methotrexate in Prospectively Defined Biomarker Patient Population

2008-07-23 09:01:21

Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today reported additional efficacy data from the company's recent regulatory filings seeking approval of ADVEXIN(R) (p53 tumor suppressor therapy) in the United States and Europe.

Introgen to Present ADVEXIN Phase 3 Study Results at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference

2008-07-17 09:01:20

Introgen Therapeutics, Inc.

More News (55 articles) »

News - Introgen Therapeutics Inc.

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health